News
Showing all blog posts in the News category.
Black-Market Retatrutide: Reported Deaths and Real Dangers
Two deaths linked to black-market 'Reta' were reported to the FDA in 2026. What the reports say, what lab tests found, and why the cause is unproven.
Retatrutide Black Market, Late 2026: Lawsuits, FDA Letters, Counterfeits
Lilly sued six sellers, the FDA named 'GLP-3 Reta' in warning letters, grey-market users lost half the trial weight, and a counterfeit vial was 8x semaglutide.
TRIUMPH-2 and TRIUMPH-3 Results: Retatrutide in Diabetes and Heart Disease
Eli Lilly's July 23, 2026 readouts: -20.8% weight loss with type 2 diabetes, -22.6% with cardiovascular disease, dysesthesia 6-7%, and a filing planned for Q1 2027.
TRIUMPH-1 Phase 3 Results: Retatrutide Delivers 28.3% Weight Loss in 2,339-Patient Obesity Trial
TRIUMPH-1, retatrutide's main Phase 3 obesity trial (2,339 adults): 28.3% average weight loss at 12 mg over 80 weeks. Results, side effects, what's next.
Retatrutide in the Context of the GLP-1 Revolution
GLP-1 drugs changed obesity and diabetes care. How retatrutide, a triple agonist, builds on semaglutide and tirzepatide, and what it adds.